Clinical Trials

NCT Number: NCT06125145 Phase: PHASE2 Trial Summary: The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and m – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): […]

NCT Number: NCT06172478 Phase: PHASE2 Trial Summary: This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/a – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Daiichi Sankyo Acronym:

NCT Number: NCT06190899 Phase: PHASE1|PHASE2 Trial Summary: This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Celcuity Inc Acronym:

NCT Number: NCT05726292 Phase: PHASE2 Trial Summary: Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as h – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT05799248 Phase: PHASE3 Trial Summary: Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): MidLantic Urology Acronym:

NCT Number: NCT05939414 Phase: PHASE3 Trial Summary: The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after defini – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Novartis Pharmaceuticals Acronym: PSMA-DC

NCT Number: NCT05125016 Phase: Phase 1|Phase 2 Trial Summary: To assess the safety, tolerability, and pharmacokinetics (PK) and to determine recommended phase 2 dosing regimen (RP2DR) of REGN4336 separately as monotherapy or in combination wi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Regeneron Pharmaceuticals Acronym:

NCT Number: NCT05155046 Phase: Phase 2 Trial Summary: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET s – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT05099679 Phase: NA Trial Summary: Pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and improve wellbeing for black m – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Stanford University Acronym:

NCT Number: NCT04927663 Phase: Phase 1 Trial Summary: This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients wit – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym: